Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.45 |
| ▸ | BRD4 | O60885 | 7/20 | 0.45 |
| ▸ | JAK2 | O60674 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 12/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | BTK | Q06187 | 3/20 | 0.44 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 4/20 | 0.44 |
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | WEE1 | P30291 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.44 |
| ▸ | BUB1B | O60566 | 1/20 | 0.44 |
| ▸ | BRD2 | P25440 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270526 | 0.91 | NUAK1 (0.48) | JAK1BRD4JAK2HDAC1JAK3 | |
| SCHEMBL309858 | 0.87 | JAK1 (0.47) | JAK1BRD4JAK2JAK3EGFR | |
| SCHEMBL17915909 | 0.86 | JAK1 (0.49) | JAK1BRD4JAK2JAK3EGFR | |
| SCHEMBL13494388 | 0.81 | BRD4 (0.57) | JAK1BRD4JAK2HDAC1JAK3 | |
| SCHEMBL14536301 | 0.81 | JAK1 (0.49) | JAK1BRD4JAK2HDAC1JAK3 | |
| SCHEMBL270609 | 0.79 | BRD4 (0.58) | JAK1BRD4JAK2HDAC1JAK3 | |
| SCHEMBL264206 | 0.77 | BRD4 (0.73) | JAK1BRD4JAK2JAK3RET | |
| SCHEMBL12111060 | 0.75 | BRD4 (0.58) | JAK1BRD4JAK2HDAC1JAK3 | |
| SCHEMBL12321387 | 0.75 | JAK3 (0.60) | JAK1BRD4JAK2HDAC1JAK3 | |
| SCHEMBL13868406 | 0.74 | EGFR (0.53) | BRD4JAK2JAK3EGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | JAK1 6/4885BRD4 156/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.